Hypertension and renal disease.
Chronic renal parenchymal disease is the most common cause of secondary hypertension: By the time end-stage renal disease develops, its prevalence approaches 75-85%. It was previously believed that hypertension caused arteriolar nephrosclerosis and ischemic renal injury superimposed on primary renal parenchymal disease, contributing to progressive renal insufficiency. Recently, the importance of an increased intraglomerular hydraulic pressure due to loss of renal autoregulation has been emphasized. There are several potential explanations concerning clinical studies which have not uniformly demonstrated slowing of progressive renal damage with antihypertensive therapy: Random BP measurements may not adequately reflect average BP levels, or, alternatively, the widely accepted target level of BP control may be inadequate. In a retrospective study, we found that hypertensive nephropathics had higher serum creatinine levels than normotensives; in another prospective trial we have demonstrated that enalapril is an effective antihypertensive agent in patients with IgA nephropathy, and it also ameliorates the evolution of the disease.
Cinotti
G A
GA
Division of Nephrology, University of Rome La Sapienza, Rome, Italy.
Comunian
C
C
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension; D006977:Hypertension, Renal; D015994:Incidence; D007668:Kidney / Q000503:physiopathology; D007676:Kidney Failure, Chronic; D009318:Natriuresis; D015995:Prevalence; D014882:Water-Electrolyte Balance
D000959:Antihypertensive Agents